Logo image of LCTX

LINEAGE CELL THERAPEUTICS IN (LCTX) Stock Fundamental Analysis

NYSEARCA:LCTX - NYSE Arca - US53566P1093 - Common Stock - Currency: USD

0.492  -0.01 (-2.38%)

Fundamental Rating

4

Overall LCTX gets a fundamental rating of 4 out of 10. We evaluated LCTX against 566 industry peers in the Biotechnology industry. While LCTX seems to be doing ok healthwise, there are quite some concerns on its profitability. LCTX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year LCTX has reported negative net income.
LCTX had a negative operating cash flow in the past year.
LCTX had negative earnings in each of the past 5 years.
In the past 5 years LCTX reported 4 times negative operating cash flow.
LCTX Yearly Net Income VS EBIT VS OCF VS FCFLCTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

LCTX's Return On Assets of -16.44% is amongst the best of the industry. LCTX outperforms 81.45% of its industry peers.
LCTX's Return On Equity of -23.74% is amongst the best of the industry. LCTX outperforms 83.75% of its industry peers.
Industry RankSector Rank
ROA -16.44%
ROE -23.74%
ROIC N/A
ROA(3y)-19.65%
ROA(5y)-20.55%
ROE(3y)-31.15%
ROE(5y)-32.32%
ROIC(3y)N/A
ROIC(5y)N/A
LCTX Yearly ROA, ROE, ROICLCTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

LCTX has a better Gross Margin (96.48%) than 95.23% of its industry peers.
LCTX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for LCTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.77%
GM growth 5Y1.84%
LCTX Yearly Profit, Operating, Gross MarginsLCTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

More info and screens

4

2. Health

2.1 Basic Checks

LCTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LCTX has been increased compared to 1 year ago.
Compared to 5 years ago, LCTX has more shares outstanding
The debt/assets ratio for LCTX has been reduced compared to a year ago.
LCTX Yearly Shares OutstandingLCTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
LCTX Yearly Total Debt VS Total AssetsLCTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

LCTX has an Altman-Z score of -3.16. This is a bad value and indicates that LCTX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of LCTX (-3.16) is comparable to the rest of the industry.
LCTX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
LCTX has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.16
ROIC/WACCN/A
WACC9.92%
LCTX Yearly LT Debt VS Equity VS FCFLCTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 3.65 indicates that LCTX has no problem at all paying its short term obligations.
The Current ratio of LCTX (3.65) is comparable to the rest of the industry.
A Quick Ratio of 3.65 indicates that LCTX has no problem at all paying its short term obligations.
LCTX has a Quick ratio (3.65) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.65
Quick Ratio 3.65
LCTX Yearly Current Assets VS Current LiabilitesLCTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

LCTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.08%, which is quite impressive.
The Revenue has been growing slightly by 6.04% in the past year.
LCTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.96% yearly.
EPS 1Y (TTM)23.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)6.04%
Revenue growth 3Y29.84%
Revenue growth 5Y21.96%
Sales Q2Q%37.36%

3.2 Future

LCTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.94% yearly.
LCTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.03% yearly.
EPS Next Y9.9%
EPS Next 2Y22.07%
EPS Next 3Y2.66%
EPS Next 5Y27.94%
Revenue Next Year-1.86%
Revenue Next 2Y80.68%
Revenue Next 3Y85.02%
Revenue Next 5Y63.03%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LCTX Yearly Revenue VS EstimatesLCTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
LCTX Yearly EPS VS EstimatesLCTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LCTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LCTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LCTX Price Earnings VS Forward Price EarningsLCTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LCTX Per share dataLCTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.07%
EPS Next 3Y2.66%

More info and screens

0

5. Dividend

5.1 Amount

LCTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LINEAGE CELL THERAPEUTICS IN

NYSEARCA:LCTX (5/2/2025, 3:40:01 PM)

0.492

-0.01 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10 2025-03-10/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners50.74%
Inst Owner Change0.15%
Ins Owners0.56%
Ins Owner Change128.69%
Market Cap112.35M
Analysts81.54
Price Target4 (713.01%)
Short Float %12.93%
Short Ratio19.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.93%
Min EPS beat(2)-14.4%
Max EPS beat(2)54.25%
EPS beat(4)2
Avg EPS beat(4)18.4%
Min EPS beat(4)-14.4%
Max EPS beat(4)54.25%
EPS beat(8)6
Avg EPS beat(8)21.29%
EPS beat(12)8
Avg EPS beat(12)14.36%
EPS beat(16)10
Avg EPS beat(16)0.3%
Revenue beat(2)2
Avg Revenue beat(2)165.97%
Min Revenue beat(2)73.4%
Max Revenue beat(2)258.54%
Revenue beat(4)4
Avg Revenue beat(4)94.62%
Min Revenue beat(4)4.11%
Max Revenue beat(4)258.54%
Revenue beat(8)7
Avg Revenue beat(8)55.27%
Revenue beat(12)8
Avg Revenue beat(12)31.85%
Revenue beat(16)12
Avg Revenue beat(16)49.1%
PT rev (1m)-6%
PT rev (3m)-18.96%
EPS NQ rev (1m)7.89%
EPS NQ rev (3m)41.18%
EPS NY rev (1m)0%
EPS NY rev (3m)39.78%
Revenue NQ rev (1m)-6.94%
Revenue NQ rev (3m)83.08%
Revenue NY rev (1m)-30.47%
Revenue NY rev (3m)-30.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.83
P/FCF N/A
P/OCF N/A
P/B 1.43
P/tB 5.31
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.04
BVpS0.34
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.44%
ROE -23.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.48%
FCFM N/A
ROA(3y)-19.65%
ROA(5y)-20.55%
ROE(3y)-31.15%
ROE(5y)-32.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.77%
GM growth 5Y1.84%
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 92.78%
Cap/Sales 5.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.65
Quick Ratio 3.65
Altman-Z -3.16
F-Score4
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)82.11%
Cap/Depr(5y)57.88%
Cap/Sales(3y)5.42%
Cap/Sales(5y)5.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y9.9%
EPS Next 2Y22.07%
EPS Next 3Y2.66%
EPS Next 5Y27.94%
Revenue 1Y (TTM)6.04%
Revenue growth 3Y29.84%
Revenue growth 5Y21.96%
Sales Q2Q%37.36%
Revenue Next Year-1.86%
Revenue Next 2Y80.68%
Revenue Next 3Y85.02%
Revenue Next 5Y63.03%
EBIT growth 1Y13.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.48%
EBIT Next 3Y4.35%
EBIT Next 5Y0.31%
FCF growth 1Y19.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.16%
OCF growth 3YN/A
OCF growth 5YN/A